HIM
VRCA icon

Hillsdale Investment Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Hillsdale Investment Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,584
Closed -$298K – 659
2023
Q1 		$298K Buy
+4,584
New +$277K 0.03% 404

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hillsdale Investment Management's VRCA Position: Q2 2023 in Review

Hillsdale Investment Management sold out of Verrica Pharmaceuticals (VRCA) in Q2 2023, closing a stake of 4,584 shares — an estimated $298K sold.

Hillsdale Investment Management first reported a position in VRCA in Q1 2023 and held it in 1 quarter. The position peaked at $298K in Q1 2023. 63 funds tracked by Wall St. Rank hold VRCA as of Q2 2023.

  • Hillsdale Investment Management reported no remaining Verrica Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 4,584 Verrica Pharmaceuticals shares in Q2 2023, an estimated $298K.
  • Hillsdale Investment Management first reported a position in Verrica Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Hillsdale Investment Management's Verrica Pharmaceuticals position peaked at $298K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2023.

Based on Hillsdale Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.